A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen
出版年份 2022 全文链接
标题
A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen
作者
关键词
-
出版物
MEDICAL ONCOLOGY
Volume 39, Issue 5, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-05-23
DOI
10.1007/s12032-022-01698-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
- (2021) Ronan J. Kelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- The TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer.
- (2021) Yasutoshi Kuboki et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
- (2021) Yelena Y Janjigian et al. LANCET
- Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors
- (2020) Anna M. Varghese et al. CLINICAL CANCER RESEARCH
- VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study
- (2020) Elizabeth Smyth et al. Frontiers in Oncology
- FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO.
- (2020) Sylvie Lorenzen et al. JOURNAL OF CLINICAL ONCOLOGY
- The prognostic value of HRD mutations in liver cancer.
- (2020) Jinzhang Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
- (2020) Yelena Y Janjigian et al. LANCET ONCOLOGY
- Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
- (2020) Aditi P. Singh et al. Cancers
- P-38 KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma
- (2020) J. Tabernero et al. ANNALS OF ONCOLOGY
- Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
- (2020) Xuan-zhang Huang et al. Frontiers in Oncology
- Peritoneal carcinomatosis in gastric cancer: Are Hispanics at higher risk?
- (2020) Audrey H. Choi et al. JOURNAL OF SURGICAL ONCOLOGY
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II study of TAS-102 in combination with ramucirumab in advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- (2019) Rutika Mehta et al. JOURNAL OF CLINICAL ONCOLOGY
- KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.
- (2019) Yelena Yuriy Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET ONCOLOGY
- Initial Report of Second‐Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi‐Institutional Retrospective Analysis
- (2018) Samuel J. Klempner et al. ONCOLOGIST
- A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials
- (2016) G Montalban-Bravo et al. LEUKEMIA
- Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives
- (2015) Marianne Ewertz et al. ACTA ONCOLOGICA
- TAS-102, a novel antitumor agent: A review of the mechanism of action
- (2015) Heinz-Josef Lenz et al. CANCER TREATMENT REVIEWS
- Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2′-deoxy-5-fluorouridine into DNA
- (2015) KAZUKI SAKAMOTO et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer
- (2015) Toshihiko Doi et al. INVESTIGATIONAL NEW DRUGS
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) T. Waddell et al. ANNALS OF ONCOLOGY
- Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial
- (2013) Shuichi Hironaka et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort
- (2013) Marcello Maugeri-Saccà et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy
- (2012) Sun Jin Sym et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Japanese gastric cancer treatment guidelines 2010 (ver. 3)
- (2011) Gastric Cancer
- Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies
- (2010) Shinichi Hasegawa et al. Gastric Cancer
- Recent patterns in gastric cancer: A global overview
- (2009) Paola Bertuccio et al. INTERNATIONAL JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started